Program
HRS-4729
A development code. Also written as “HRS-4729 Injection”, “HRS-4729 Injection;” and “HRS-4729 injection”.
In Jiangsu HengRui Medicine's pipeline, GLP-1/GIP/ GCG
. Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Fatty Liver, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 54 open or running | phase 2since Jun 16, 2026 | Dec 31, 2024 | Mar 2027phase 2 · NCT07690826 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-4729
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 31, 2024First study: phase 1 study in OverweightFirst studyNCT06762600 · 102 enrolled · China
- Jun 16, 2026Phase 2 study in Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 2 reachedNCT07660848 · 160 planned · China
- Jul 1, 2026Phase 2 study in OverweightNCT07690826 · 252 planned · China
- Aug 17, 2026Phase 1 study in OverweightNCT07807059 · 32 planned · China
- Sep 22, 2026Phase 2 study in Diabetes Mellitus, Type 2NCT07843862 · 240 planned · China
Ahead
- Mar 2027Primary completion: phase 2 study in OverweightNCT07690826
- Mar 15, 2027Primary completion: phase 1 study in OverweightNCT07807059
- Apr 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07843862
- Mar 2028Primary completion: phase 2 study in Metabolic Dysfunction-Associated Steatohepatitis (MASH)NCT07660848
TargetBeta
“GLP-1/GIP/ GCG”the company's pipeline, read by Claude · source
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| UBT251 | The United Laboratories International | phase 3 | 12 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07843862Diabetes Mellitus, Type 2 · China | 2 | Not yet recruiting | Apr 2027 | 240 |
| NCT07807059Overweight · China | 1 | Recruiting | Mar 15, 2027 | 32 |
| NCT07690826Overweight · China | 2 | Not yet recruiting | Mar 2027 | 252 |
| NCT07660848Metabolic Dysfunction-Associated Steatohepatitis (MASH) · China | 2 | Recruiting | Mar 2028 | 160 |
| NCT06762600Overweight · China | 1 | Completed | Mar 12, 2026 | 102 |
How it is read
Names in the registry
- “HRS-4729 Injection”, 5 entries
- “HRS-4729 Injection;”, 3 entries
- “HRS-4729”, 1 entry
- “HRS-4729 injection”, 1 entry
Codes read as this program: HRS4729.
Conditions, from the studies’ own filings
- Obesity, 3 studies
- Diabetes Mellitus, Type 2, 1 study
- Fatty Liver, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.